NATIONAL HARBOR, Md., May 15, 2015 /PRNewswire/ -- New data from an ongoing post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) in patients with non-valvular atrial fibrillation (NVAF) were presented at the American Geriatrics Society 2015 Annual...
No comments:
Post a Comment